TB-500: What It Is, Where to Get It Prescribed, and What It Costs

TB-500 is a synthetic peptide built around the actin-binding region of thymosin beta-4, a 43-amino-acid protein that is one of the most abundant small proteins inside human cells and whose main job is to hold actin monomers in reserve. Actin gives a cell its internal scaffolding and lets it change shape and move. The stretch that binds actin is a short sequence, LKKTETQ, at positions 17 to 23 of the parent protein, and that sequence is the core of what is supplied as TB-500.

That is why the compound is discussed in the context of repair. Injured tissue needs cells to migrate into the damaged area, moving requires rearranging actin, and thymosin beta-4 is released by platelets at the site of injury — which led researchers in the 1990s to ask whether giving more of it changed how a wound closed.

"TB-500" is a product name, not a scientific one. The published papers are about thymosin beta-4, written Tβ4, and most used the full-length protein. A smaller body of work looked at the fragment: a 2003 paper in Wound Repair and Regeneration tested the seven-amino-acid LKKTETQ peptide alongside the full protein in aged mice and reported it promoted repair comparably to the parent molecule, and a 2010 paper in the FASEB Journal mapped which activities short sequences could reproduce. So when this page says "the research describes," it usually means thymosin beta-4, with the fragment studied in a subset.

TB-500 is not a hormone, not a steroid, and not a growth factor in the strict sense — it does not act through a growth hormone or IGF-1 pathway. It is not thymosin alpha-1, a different thymic peptide with an immune-focused literature; the shared word dates from when both were first isolated from thymus extracts. It is not a painkiller, and it is not a treatment for a structural problem: a complete rupture or a displaced fracture is a surgical question. And it has no meaningful oral route — unlike BPC-157, there is no published stability in gastric acid.

The foundational mechanism. Thymosin beta-4 binds monomeric actin, and by controlling the free actin supply it influences how readily a cell can build the filaments needed to crawl. A 1997 paper in the FASEB Journal reported thymosin beta-4 stimulating directional migration of human umbilical vein endothelial cells in culture. A 2005 review in Trends in Molecular Medicine frames this as the molecule "moonlighting": a housekeeping actin-buffer that, once released after injury, also acts as a signal drawing repair cells into the wound. It is the mechanism most directly tied to the fragment, since the actin-binding domain is what TB-500 is.

Endothelial cells build blood vessels, so an effect on their migration leads naturally to angiogenesis. A 2004 paper in Mechanisms of Ageing and Development reported thymosin beta-4 promoting angiogenesis and wound healing in mice, and a 2007 paper in Nature described it mobilising adult epicardial progenitor cells and driving new vessel growth in the mouse heart. The logic for soft tissue is the same as for BPC-157: tendon and ligament are poorly vascularised, and blood supply often limits recovery.

A 2004 paper in Nature reported thymosin beta-4 activating integrin-linked kinase and the downstream Akt survival pathway in cardiac cells, with treated mice recovering more cardiac function after an induced heart attack than untreated animals. This is the paper that turned thymosin beta-4 into a serious research programme, and why much of the later literature is cardiac rather than musculoskeletal. It is a mouse finding.

A corneal research group describes thymosin beta-4 suppressing NF-κB, the transcription factor that switches on many inflammatory genes — in corneal cells in a 2007 paper in Experimental Eye Research, and against TNF-α-driven NF-κB activation in a 2011 paper in the FASEB Journal. This is a described pathway in cells and animal eyes, not a demonstrated anti-inflammatory effect in a human joint or tendon.

Wound closure needs cells to lay down and then reorganise extracellular matrix. A 2004 paper in Experimental Cell Research reported thymosin beta-4 stimulating production of laminin-5, a protein that anchors epithelial cells to the tissue beneath them, and a 2006 paper in the Journal of Cellular Physiology described it promoting matrix metalloproteinase expression during wound repair. Reduced scarring in some animal models is generally attributed to this together with the anti-inflammatory effect.

The original and best-developed area. The 1999 paper in the Journal of Investigative Dermatology reported that thymosin beta-4, given topically or by intraperitoneal injection, increased re-epithelialisation of full-thickness skin wounds in rats, with more collagen deposition and angiogenesis than saline controls. The 2003 Wound Repair and Regeneration paper extended that to diabetic (db/db) and aged mice, both models of impaired healing, and included the LKKTETQ fragment.

A 2002 paper in Experimental Eye Research reported thymosin beta-4 promoting corneal healing and reducing inflammation after alkali injury in mice, and a 2002 paper in Current Eye Research reported it promoting migration of human conjunctival epithelial cells in culture. This line of work eventually produced human trials.

The 2004 and 2007 Nature papers are the anchors, and a 2023 paper in Cardiovascular Research reported thymosin beta-4 and the related prothymosin alpha promoting cardiac regeneration after ischaemic injury in mice. Strong preclinical work, but about rodent heart muscle after an induced infarct.

The indication most people asking about TB-500 care about, and the thinnest part of the literature. The case is an inference from the dermal and cardiac work — the same pathways ought to matter in a tendon — rather than a body of tendon studies. A 2026 paper in Joint Diseases and Related Surgery examined BPC-157 and TB-500 in Achilles tendon healing in rats, one of the first papers to test the compound by name in an orthopaedic model.

There are no randomised controlled trials of TB-500 — the actin-binding fragment given by subcutaneous injection — in humans, for any indication. The tendon, ligament and muscle case rests entirely on animal and cell research plus clinical prescribing experience.

Full-length thymosin beta-4 is a different matter; it has been through a formal drug-development programme. A 2007 paper in the Annals of the New York Academy of Sciences described that programme for ischaemic heart disease, including a Phase 1 protocol to assess safety, tolerability and pharmacokinetics in healthy volunteers. A 2015 paper in Cornea reported a Phase 2 randomised, placebo-controlled trial of thymosin beta-4 eye drops in patients with severe dry eye, describing improvement in signs and symptoms versus placebo. A 2012 paper in the Annals summarised two Phase 2 trials in pressure ulcers and venous stasis ulcers, reporting faster healing in the patients whose wounds did heal.

Notice what those are: the full protein, as eye drops or applied to a wound, in eye and skin conditions. None used the TB-500 fragment, none used subcutaneous injection, and none looked at a tendon or a joint. Any source citing "human trials of TB-500" for injury recovery is borrowing evidence from a different molecule, route and disease. The honest framing is: described in preclinical research, with human trials of the parent protein in unrelated indications, and used clinically on that basis.

• It does not establish an effect size in humans for any musculoskeletal injury. That trial has not been run.
• It does not establish a timeline in humans. Prescriber timelines are clinical experience, not trial endpoints.
• It does not establish that the fragment reproduces every effect of the full protein.
• It does not establish long-term safety over years of continuous use.
• It does not establish efficacy for any condition as an FDA-approved treatment. Neither TB-500 nor thymosin beta-4 is approved for anything.

Most people notice nothing in this window, and that is normal. What is sometimes reported early is background soreness settling, which — if it reflects anything — would be the inflammatory-signalling side of the research rather than tissue change.

Based on the animal timelines, this is where cell migration and vessel growth into injured tissue would be expected to matter if they occur, and a single vial is sized to cover it.

A recent injury with a clear onset is generally described by prescribers as more responsive than a tendon that has been sore for a year. Chronic cases are described as slower and less predictable — worth raising with your physician before starting rather than after.

There is no withdrawal or rebound described in the literature; thymosin beta-4 is a protein your body already makes in quantity. Whether any benefit persists depends on whether the underlying tissue actually changed, the same question that applies to any recovery intervention.

The directions are written in millilitres and in insulin-syringe units because that is what you can read off the barrel. 0.25 mL is 25 units on a U-100 syringe. You are not calculating anything — the number is printed on your medication.

Subcutaneous means into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated. The mechanisms described in the research are systemic, so most prescribers do not direct injection near the injured area; if yours does, your directions will say.

The reviewed schedule is Monday through Friday mornings with weekends off. At five doses a week, 20 doses is exactly four weeks, which is why refills run on a 28-day cycle. One vial per fill, always — not a stockpile.

Refrigerated, and it ships that way in insulated packaging with ice packs. Beyond-use dating runs from first puncture and is on the label. Do not freeze it.